$30 million equity stake in BioAtla by China-based investor group

11 June 2015

San Diego, USA-based biotech firm BioAtla, which is focused on the development of conditionally active biologic (CAB) antibody therapeutics, says that a China-based investor group has purchased $30 million in BioAtla equity.

The proceeds will be used to accelerate the development of the company's CAB antibody drug pipeline. This strategic investment also will advance BioAtla's plans to collaboratively develop biotherapeutics with biopharmaceutical companies and institutions in China to address the high demand for innovative therapeutic products and the growing demand in the China pharmaceutical market.

BioAtla's patent protected CAB platform represents a disruptive technology for the development of a powerful new class of immuno-therapeutics that are activated in selected microenvironments within the body such as those indicative of cancerous tumors. CABs can be generated in several different formats including naked monoclonal antibodies (MAbs) antibody drug conjugates immune checkpoint inhibitors bispecific antibodies and chimeric antigen receptor (CAR) T cells.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK